PART I
FINANCIAL INFORMATION

Item 1 - Financial Statements (unaudited)

Consolidated Balance Sheets as of June 30, 2004 and December 31, 2003
Consolidated Statements of Operations for the three and six months ended June 30, 2004 and 2003
Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2004 and 2003
Consolidated Statements of Cash Flows for the six months ended June 30, 2004 and 2003
Notes to Consolidated Financial Statements

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

Item 4 - Controls and Procedures

PART II
OTHER INFORMATION

Item 4 – Submission of Matters to a Vote of Security Holders

Item 6 - Exhibits and Reports on Form 8-K
### Assets

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2004</th>
<th>December 31, 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents $3,133</td>
<td>$10,700</td>
<td></td>
</tr>
<tr>
<td>Investment securities, available-for-sale $3,521</td>
<td>$11,078</td>
<td></td>
</tr>
<tr>
<td>Accounts receivable, net of allowances of $133 and $109 $1,577</td>
<td>$1,896</td>
<td></td>
</tr>
<tr>
<td>Costs and estimated earnings in excess of billings on uncompleted contracts $785</td>
<td>$664</td>
<td></td>
</tr>
<tr>
<td>Inventory $2,821</td>
<td>$331</td>
<td></td>
</tr>
<tr>
<td>Other current assets $2,122</td>
<td>$1,684</td>
<td></td>
</tr>
<tr>
<td><strong>Total current assets</strong> $13,959</td>
<td>$26,353</td>
<td></td>
</tr>
<tr>
<td><strong>Property and equipment, net</strong> $5,224</td>
<td>$5,958</td>
<td></td>
</tr>
<tr>
<td><strong>Restricted investments</strong> $1,238</td>
<td>$1,269</td>
<td></td>
</tr>
<tr>
<td><strong>Other assets</strong> $267</td>
<td>$338</td>
<td></td>
</tr>
<tr>
<td><strong>Total assets</strong> $20,688</td>
<td>$33,918</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2004</th>
<th>December 31, 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liabilities, Minority Interests and Shareholders’ Equity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable $3,303</td>
<td>$1,223</td>
<td></td>
</tr>
<tr>
<td>Accrued liabilities $4,781</td>
<td>5,164</td>
<td></td>
</tr>
<tr>
<td>Current portion of research liability $78</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Billings in excess of costs and estimated earnings on uncompleted contracts $50</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Current portion of notes payable $2,085</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Current portion of capital lease obligations $45</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Current portion of long-term debt $74</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td><strong>Total current liabilities</strong> $10,416</td>
<td>6,572</td>
<td></td>
</tr>
<tr>
<td><strong>Research liability, net of current portion</strong> —</td>
<td>1,948</td>
<td></td>
</tr>
<tr>
<td><strong>Capital lease obligations, net of current portion</strong> $11</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td><strong>Long-term debt, net of current portion</strong> $62</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td><strong>Deferred rent, net of current portion</strong> $64</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td><strong>Other long-term liabilities</strong> $244</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td><strong>Total liabilities</strong> $10,797</td>
<td>8,776</td>
<td></td>
</tr>
<tr>
<td><strong>Commitments and Contingencies</strong> —</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td><strong>Minority Interests</strong> $1,030</td>
<td>1,847</td>
<td></td>
</tr>
<tr>
<td><strong>Shareholders’ Equity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common stock, par value $.001; 73,000 shares authorized; 21,506 and 21,449 shares issued and outstanding 22</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Paid-in capital $180,940</td>
<td>$180,354</td>
<td></td>
</tr>
<tr>
<td>Preferred stock, par value $.001; 25,000 shares authorized; 0 shares issued and outstanding —</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Deferred compensation $(642)</td>
<td>$(846)</td>
<td></td>
</tr>
<tr>
<td>Subscriptions receivable from related parties $(166)</td>
<td>$(166)</td>
<td></td>
</tr>
<tr>
<td>Receivables from related parties, net $(1,823)</td>
<td>$(1,823)</td>
<td></td>
</tr>
<tr>
<td>Accumulated other comprehensive income 25</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td><strong>Accumulated deficit</strong> $(169,472)</td>
<td>$(154,270)</td>
<td></td>
</tr>
<tr>
<td><strong>Total shareholders’ equity</strong> $8,861</td>
<td>23,295</td>
<td></td>
</tr>
<tr>
<td><strong>Total liabilities, minority interests and shareholders’ equity</strong> $20,688</td>
<td>$33,918</td>
<td></td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these financial statements.

---

**Microvision, Inc.**

**Consolidated Statement of Operations**

(In thousands, except earnings per share data)

(Unaudited)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended June 30, 2004</th>
<th>Six months ended June 30, 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contract revenue $1,811</td>
<td>$4,364</td>
<td>$4,110</td>
</tr>
<tr>
<td>Product revenue $587</td>
<td>$147</td>
<td>$1,262</td>
</tr>
<tr>
<td><strong>Total revenue</strong> $2,398</td>
<td>$4,511</td>
<td>$5,372</td>
</tr>
<tr>
<td>Cost of contract revenue $1,192</td>
<td>2,052</td>
<td>2,397</td>
</tr>
<tr>
<td>Cost of product revenue $638</td>
<td>$149</td>
<td>$1,303</td>
</tr>
<tr>
<td><strong>Total cost of revenue</strong> $1,830</td>
<td>$2,201</td>
<td>$3,700</td>
</tr>
<tr>
<td><strong>Gross margin</strong> $568</td>
<td>$2,310</td>
<td>$1,672</td>
</tr>
</tbody>
</table>

Research and development expense (exclusive of non-cash compensation expense of $281 and $251 for the three months and $566 and $503 for the six months ended June 30, 2004 and 2003, respectively) $3,343 | $6,079 | 7,962 | 12,879
Marketing, general and administrative expense (exclusive of non-cash compensation expense of $652 and $201 for the three months and $1,050 and $414 for the six months ended June 30, 2004 and 2003, respectively)  

<table>
<thead>
<tr>
<th></th>
<th>Three months ended June 30, 2004</th>
<th>Three months ended June 30, 2003</th>
<th>Six months ended June 30, 2004</th>
<th>Six months ended June 30, 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-cash compensation expense</td>
<td>933</td>
<td>452</td>
<td>1,616</td>
<td>917</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>9,467</td>
<td>10,917</td>
<td>19,342</td>
<td>22,467</td>
</tr>
<tr>
<td>Loss from operations</td>
<td>(8,899)</td>
<td>(8,607)</td>
<td>(17,670)</td>
<td>(18,029)</td>
</tr>
<tr>
<td>Interest income</td>
<td>79</td>
<td>91</td>
<td>181</td>
<td>214</td>
</tr>
<tr>
<td>Interest expense</td>
<td>(89)</td>
<td>(10)</td>
<td>(97)</td>
<td>(24)</td>
</tr>
<tr>
<td>Gain (loss) on disposal of fixed assets, net</td>
<td>—</td>
<td>(31)</td>
<td>—</td>
<td>(31)</td>
</tr>
<tr>
<td>Realized gain on sale of investment securities</td>
<td>—</td>
<td>12</td>
<td>—</td>
<td>39</td>
</tr>
<tr>
<td>Loss before minority interests</td>
<td>(8,909)</td>
<td>(8,545)</td>
<td>(17,586)</td>
<td>(17,831)</td>
</tr>
<tr>
<td>Minority interests in loss of consolidated subsidiary</td>
<td>397</td>
<td>1,853</td>
<td>2,384</td>
<td>3,743</td>
</tr>
<tr>
<td>Net loss</td>
<td>$ (8,512)</td>
<td>$ (6,692)</td>
<td>$ (15,202)</td>
<td>$ (14,088)</td>
</tr>
<tr>
<td>Net loss per share - basic and diluted</td>
<td>$ (0.40)</td>
<td>$ (0.38)</td>
<td>$ (0.71)</td>
<td>$ (0.83)</td>
</tr>
<tr>
<td>Weighted-average shares outstanding - basic and diluted</td>
<td>21,497</td>
<td>17,799</td>
<td>21,478</td>
<td>16,878</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these financial statements.

Microvision, Inc.

Consolidated Statement of Comprehensive Loss  
(In thousands)  
(Unaudited)  

<table>
<thead>
<tr>
<th></th>
<th>Three months ended June 30, 2004</th>
<th>Three months ended June 30, 2003</th>
<th>Six months ended June 30, 2004</th>
<th>Six months ended June 30, 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net loss</td>
<td>$ (8,512)</td>
<td>$ (6,692)</td>
<td>$ (15,202)</td>
<td>$ (14,088)</td>
</tr>
</tbody>
</table>
| Other comprehensive income (loss) -  
  Unrealized gain (loss) on investment securities, available-for-sale:  
  Unrealized holding gains (losses) arising during period | (9)                             | (16)                            | (23)                          | (30)                          |
| Less: reclassification adjustment for gains realized in net loss | —                               | (12)                            | —                             | (39)                          |
| Net unrealized gain (loss) | (9)                             | (28)                            | (23)                          | (69)                          |
| Comprehensive loss       | $ (8,521)                       | $ (6,720)                       | $ (15,225)                    | $ (14,157)                    |

The accompanying notes are an integral part of these financial statements.

Microvision, Inc.

Consolidated Statement of Cash Flows  
(In thousands)  
(Unaudited)

<table>
<thead>
<tr>
<th>Cash flows from operating activities</th>
<th>Six months ended June 30, 2004</th>
<th>Six months ended June 30, 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net loss</td>
<td>$ (15,202)</td>
<td>$ (14,088)</td>
</tr>
</tbody>
</table>
| Adjustments to reconcile net loss to net cash used in operations:  
  Depreciation                         | 1,378                          | 1,632                          |
  Gain (loss) on disposal of fixed assets | —                              | 31                             |
  Non-cash expenses related to issuance of stock, warrants, options and amortization of deferred compensation | 1,616                          | 917                            |
  Allowance for receivables from related parties | —                              | 200                            |
  Realized gain on sale of investment securities | —                              | (39)                           |
  Minority interests in loss of consolidated subsidiary | (2,384)                        | (3,743)                        |
  Non-cash deferred rent               | (43)                           | (43)                           |
  Interest on Notes Payable            | 86                             | —                              |
| Change in:                           |                                |                                |
  Accounts receivable                  | 319                            | (1,161)                        |
  Costs and estimated earnings in excess of billings on uncompleted contracts | (121)                          | (372)                          |
  Inventory                            | (2,490)                        | 297                            |
  Other current assets                 | (597)                          | 325                            |
  Other assets                         | 71                             | 20                             |
Accounts payable 2,021 (73)
Accrued liabilities 418 880
Billings in excess of costs and estimated earnings on uncompleted contracts 3 (111)
Research liability, current and long-term 1,870 977
Net cash used in operating activities 17,637 (14,351)

Cash flows from investing activities
Sales of investment securities 8,589 2,779
Purchases of investment securities (1,055 )
Sales of restricted investment securities 1,269 1,356
Purchases of restricted investment securities (1,238 ) (1,269 )
Purchases of property and equipment (585 ) (628 )
Net cash provided by investing activities 6,980 2,238

Cash flows from financing activities
Principal payments under capital leases (40 ) (45 )
Proceeds from issuance of short-term notes 2,300 —
Principal payments under long-term debt (33 ) (30 )
Net proceeds from issuance of common stock 363 11,591
Net proceeds from sale of subsidiary’s equity to minority interests 500 —
Net cash provided by financing activities 3,090 11,516
Net decrease in cash and cash equivalents (7,567 ) (597 )
Cash and cash equivalents at beginning of period 10,700 9,872
Cash and cash equivalents at end of period $ 3,133 $ 9,275

The accompanying notes are an integral part of these financial statements.

Supplemental disclosure of cash flow information
Cash paid for interest $ 11 $ 24

Supplemental schedule of non-cash investing and financing activities
Other non-cash additions to property and equipment $ 88 $ 45

The accompanying notes are an integral part of these financial statements.

MICROVISION, INC.
Notes to Consolidated Financial Statements
June 30, 2004

Management’s Statement

The consolidated financial statements include the accounts of Microvision, Inc. (“Microvision”); a Delaware corporation, and its subsidiary Lumera Corporation (“Lumera”), a Washington corporation, (collectively the “Company”). As of June 30, 2004 and December 31, 2003 Microvision owned 76% of the common stock, 11% of the Series A and 27% of the Series B convertible preferred stock and 76% of the common stock, 11% of the Series A and 32% of the Series B convertible preferred stock, respectively. At June 30, 2004 balance of Lumera’s outstanding capital stock was owned by its directors, Microvision employees, the University of Washington and other investors unaffiliated with the Company. Lumera’s losses were first allocated to its common shareholders until such losses exceeded its common equity and then to its preferred shareholders pro rata in accordance with their respective liquidation values. All material intercompany accounts and transactions have been eliminated in consolidation.

In July 2004, Lumera completed an initial public offering of its common stock. In connection with the offering, all Lumera Series A and Series B Preferred Stock was converted to Lumera common stock. Immediately after the offering Microvision owned 5,434,000 shares or 33% of the common stock of Lumera. As a result of the change in ownership percentage, Microvision will change the method of accounting for its investment in Lumera to the equity method. Microvision expects to record a non-cash
Standards ("SFAS") No. 123, "Accounting for Stock-Based Compensation." The Company accounts for ("FIN") 44, "Accounting for Certain Transactions Involving Stock Compensation," and complies with the disclosure provisions of Statement of Financial Accounting "Accounting for Stock Issued to Employees" and related amendments and interpretations including the Financial Accounting Standards Board (FASB) Interpretation Number ("FIN") 2004 and 2003, Lumera had outstanding options and warrants to purchase 1,941,000 and 943,000 shares of common stock, respectively. As of June 30, 2004 and 2003, Microvision had outstanding options and warrants to purchase 6,029,000 and 6,317,000 shares of common stock, respectively. The components of basic and diluted earnings per share were as follows (in thousands except earnings per share data):

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2004</th>
<th>December 31, 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raw materials</td>
<td>$1,700,000</td>
<td>$98,000</td>
</tr>
<tr>
<td>Work in process</td>
<td>112,000</td>
<td></td>
</tr>
<tr>
<td>Finished goods</td>
<td>1,009,000</td>
<td>233,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$2,821,000</td>
<td>$331,000</td>
</tr>
</tbody>
</table>

The inventory at June 30, 2004 and December 31, 2003 consisted of raw materials, work in process and finished goods for Nomad and Flic. Inventory is stated at the lower of cost or market, with cost determined on a weighted average basis. Management periodically assesses the need to provide for obsolescence of inventory and adjusts the carrying value of inventory to its net realizable value when required.

Amendment to University of Washington Agreement

In April 2004, Lumera and the University of Washington entered into a fourth amendment to the Sponsored Research Agreement that requires payments of $125,000 for the quarters ending March 31, 2004 and June 30, 2004 and eliminates a contingent payment of $2,000,000. For each of the quarters ending September 30, 2004 and December 31, 2004 Lumera is required to pay $250,000. The agreement will terminate in 2005 after payments of $375,000 are made in each of the quarters ending March 31, 2005 and June 30, 2005. Total payments under the Sponsored Research Agreement will be $5,750,000 instead of the original $9,000,000.

Lumera recognizes research and development expense under the Sponsored Research Agreement on a straight line basis over the term of the agreement. At the time of the fourth amendment to the Sponsored Research Agreement, Lumera had recognized $6.5 million in cumulative expense related to the Sponsored Research Agreement. In April 2004, Lumera recorded a reduction in its liability and an offsetting reduction in expense of $2.4 million to reduce the cumulative expense recognized under the Sponsored Research Agreement to the expense incurred under the fourth amendment on a straight line basis. Lumera will continue to recognize approximately $325,000 per quarter in expense on the Sponsored research agreement until it expires in June 2005.

Convertible Promissory Notes

In April 2004, Lumera raised $2,300,000 from the issuance of convertible promissory notes. The notes accrue interest at a rate of 6.5% per annum and are payable on demand following the closing of the underwritten public offering of Lumera’s common stock in July 2004. The principal amount and any accrued but unpaid interest in respect of each note is convertible at any time, at the option of the holder, into shares of Lumera’s common stock. The conversion price is $6.00 per share of common stock.

In connection with the sale of the convertible notes, Lumera also issued warrants to purchase shares of common stock. The number of shares is based on a formula based on the exercise price of the warrant and the face amount of the holder’s convertible note. The exercise price of the warrants is $7.20 per share. All of the warrants are exercisable on the date of grant and expire in April 2009. The value of the warrants granted was estimated to be approximately $344,000 using the Black Scholes option pricing model. The relative fair value of the warrants of $299,000 will be treated as a debt issuance cost and is being amortized to interest expense over the one year term of the convertible notes.

Net Loss Per Share

Basic net loss per share is calculated on the basis of the weighted-average number of common shares outstanding during the reporting periods. Diluted net loss per share is calculated on the basis of the weighted-average number of common shares outstanding and taking into account the dilutive effect of all potential common stock equivalents outstanding. Diluted net loss per share for the three and six months ended June 30, 2004 is equal to basic net loss per share because the effect of potential common stock outstanding during the periods, including options and warrants, is anti-dilutive.

The components of basic and diluted earnings per share were as follows (in thousands except earnings per share data):

<table>
<thead>
<tr>
<th></th>
<th>Three months ended June 30,</th>
<th>Six months ended June 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2004</td>
<td>2003</td>
</tr>
<tr>
<td>Numeral:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net loss available</td>
<td>$ (8,512)</td>
<td>$ (6,692)</td>
</tr>
<tr>
<td>Denominator:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic and diluted weighted-average common shares outstanding</td>
<td>21,497</td>
<td>17,799</td>
</tr>
<tr>
<td>Basic and diluted weighted loss per share</td>
<td>$. (.40)</td>
<td>$. (38)</td>
</tr>
</tbody>
</table>

As of June 30, 2004 and 2003, Microvision had outstanding options and warrants to purchase 6,029,000 and 6,317,000 shares of common stock, respectively. As of June 30, 2004 and 2003, Lumera had outstanding options and warrants to purchase 1,941,000 and 943,000 shares of common stock, respectively.

Stock-Based Compensation

equity instruments issued to non-employees in accordance with the provisions of SFAS No. 123 and Emerging Issues Task Force Issue No. 96-18.

Total non-cash stock-based compensation expense related to employee and director awards included in the determination of net loss was $558,000 and $28,000 for the three months ended June 30, 2004 and 2003; and $798,000 and $73,000 for the six months ended June 30, 2004 and 2003, respectively. Had compensation expense for employee and director options been determined using the fair values at the grant dates consistent with the methodology prescribed under SFAS No. 123, the Company’s consolidated net loss available to common shareholders and associated net loss per share would have increased to the pro forma amounts indicated below (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Three Months Ended June 30</th>
<th>Six Months Ended June 30</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2004</td>
<td>2003</td>
</tr>
<tr>
<td>Net Loss available for common shareholders, as reported</td>
<td>$ (8,512)</td>
<td>$ (6,692)</td>
</tr>
<tr>
<td>Add: Stock-based employee compensation expense included in net loss available for common shareholders, as reported</td>
<td>86</td>
<td>27</td>
</tr>
<tr>
<td>Deduct: Stock-based employee compensation expense determined under fair value based method for all awards</td>
<td>(1,141)</td>
<td>(2,071)</td>
</tr>
<tr>
<td>Net Loss available for common shareholders, pro forma</td>
<td>$ (9,567)</td>
<td>$ (8,736)</td>
</tr>
<tr>
<td>Net Loss per share (Basic and diluted) As reported</td>
<td>$ (40)</td>
<td>$ (38)</td>
</tr>
<tr>
<td>Pro Forma</td>
<td>$ (45)</td>
<td>$ (49)</td>
</tr>
</tbody>
</table>

Weighted average Shares outstanding

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>21,497</td>
<td>17,799</td>
</tr>
<tr>
<td></td>
<td>21,478</td>
<td>16,878</td>
</tr>
</tbody>
</table>

Equity

In March 2004, Lumera raised $500,000, before issuance costs, from the sale of 250,000 shares of Series B convertible preferred stock to a group of private investors. Microvision did not participate in the offering.

Segment Information

The Company is organized into two segments - Microvision, which is engaged in the development and commercialization of scanned beam technology for information displays and image capture products, and Lumera, which is engaged in the development and commercialization of products utilizing its optical materials technology. The segments were determined based on how management views and evaluates the Company’s operations.

The following table reflects the results of the Company’s reportable segments under the Company’s financial management system. The performance of each segment is measured based on several metrics. These results are used, in part, by management in evaluating the performance of, and in allocation of resources to, each of the segments. The Company does not expect Lumera to be a reportable segment beginning in the third quarter of 2004.

<table>
<thead>
<tr>
<th></th>
<th>Three months ended June 30, 2004</th>
<th>Three months ended June 30, 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Microvision (in thousands)</td>
<td>Lumera</td>
</tr>
<tr>
<td>Contract revenue</td>
<td>$ 1,523</td>
<td>$ 288</td>
</tr>
<tr>
<td>Product revenue</td>
<td>587</td>
<td>—</td>
</tr>
<tr>
<td>Cost of contract revenue</td>
<td>1,004</td>
<td>188</td>
</tr>
<tr>
<td>Cost of product revenue</td>
<td>638</td>
<td>—</td>
</tr>
<tr>
<td>Research and development expense</td>
<td>4,436</td>
<td>(963)</td>
</tr>
<tr>
<td>Marketing, general and administrative expense</td>
<td>4,400</td>
<td>751</td>
</tr>
<tr>
<td>Non-cash compensation expense</td>
<td>168</td>
<td>765</td>
</tr>
<tr>
<td>Interest income</td>
<td>8</td>
<td>86</td>
</tr>
<tr>
<td>Interest expense</td>
<td>8</td>
<td>38</td>
</tr>
<tr>
<td>Segment loss</td>
<td>8</td>
<td>538</td>
</tr>
<tr>
<td>Depreciation</td>
<td>397</td>
<td>298</td>
</tr>
<tr>
<td>Expenditures for capital assets</td>
<td>23,794</td>
<td>4,253</td>
</tr>
</tbody>
</table>

The Company does not expect Lumera to be a reportable segment beginning in the third quarter of 2004.
ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

The information set forth in this report in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and Item 3, “Quantitative and Qualitative Disclosure about Market Risk,” includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is subject to the safe harbor created by that section. Such statements may include, but are not limited to, projections of revenues, income or loss, capital expenditures, plans for product development and cooperative arrangements, future operations, financing needs or plans of the Microvision, as well as assumptions relating to the foregoing. The words “believe,” “expect,” “will,” “anticipate,” “estimate,” “project,” “plan,” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Factors that could cause results to differ materially from those projected or implied in the forward-looking statements are set forth below under the caption “Risk Factors Relating to the Microvision’s Business.”

Overview

The company has historically included both Microvision, Inc. (“Microvision”) and its consolidated subsidiary, Lumera Corporation (“Lumera”) (collectively the “Company”). The Company designs and markets information display and image capture products and products utilizing its optical and related materials technology. Historically, the Company has developed and sought to commercialize technologies and products in two business segments relating to the display, capture and transmission of information:

- **Microvision** - Develops and commercializes scanned beam technology for information displays and image capture products.
- **Lumera** - Develops and commercializes a new class of organic non-linear optical materials that can be used to change the properties of light waves used to transmit information.

In July 2004, Lumera completed an initial public offering of its common stock. In connection with the offering, all Lumera Series A and Series B Preferred Stock was converted to Lumera common stock. Immediately after the offering Microvision owns 5,434,000 shares or 33% of the common stock of Lumera. As a result of the change in ownership percentage, Microvision will change the method of accounting for its investment in Lumera to the equity method. Microvision expects to record a non-cash change in interest gain of approximately $13.0 million during the third quarter as a result of the public offering. In connection with the Lumera initial public offering, Microvision entered into a six month lock-up agreement. During the lock-up period, Microvision can not sell or pledge as collateral its shares of Lumera stock.

**Microvision**

**Nomad**

In March 2004, Microvision introduced a new version of the Nomad Expert Technician System (“Nomad”), a head worn, monochrome red, see-through display. The new version is about 40% smaller, lighter and costs less to manufacture than the prior version. Microvision has worked closely with automotive companies, including Honda Motor Company of North America, to develop the Nomad for automotive maintenance applications. In maintenance applications, the automotive technician uses the Nomad to provide repair instructions directly in his or her field of view while he or she is performing the repair. The Nomad is linked to a computer or thin client that along with a wireless network card allows the technician wireless access to service information. In trials, technicians using the Nomad have reported substantial time savings in...
performing repairs. There are over 850,000 automotive technicians in the United States who work in facilities that have, or can easily acquire, the digital content to take advantage of the Nomad display.

The U.S. Army has deployed 100 Nomad systems in the US Army’s Stryker Brigade Combat Team, in Iraq. The helmet-mounted Nomad Augmented Vision System provides the vehicle commander with a head-up, daylight-readable, remote display of the Stryker’s onboard battlefield computer while operating from the commander’s hatch opening. The Nomad allows the commander to observe the surroundings, while choosing the optimum path ahead, commanding the vehicle and better using tactical information.

Microvision is using a contract manufacturer in Washington State to build the Nomad. Microvision will distribute the Nomad directly to end customers through its sales force, through independent manufacturers’ representatives and through original equipment manufacturers.

Flic

In 2002, Microvision introduced Flic, a hand held bar code scanner. The Flic features a proprietary design that provides for lower power consumption and cost than other currently available bar code scanners. In 2003, Microvision introduced Flic cordless, a Bluetooth enabled version of the Flic. During 2003, Microvision worked with its customers to add required features for specific markets, and with application developers to develop integrated solutions that utilize the Flic. This work resulted in an order for over 5,000 Flics from NCR during the fourth quarter of 2003. Microvision expects that the sales volume for Flic will grow as customers complete their trials and application developers release products incorporating Flic.

Flic is manufactured for Microvision by a contract manufacturer located in Batam, Indonesia. Microvision distributes Flic directly to end users through value added resellers, original equipment manufacturers such as NCR, and through phone and internet orders.

Other Applications

Microvision is continuing to develop prototype automotive head-up displays, electronic view finders, and image capture products. These prototypes demonstrate that scanned beam display technology can be used in different potential display and image capture products. Microvision believes that it can further develop these prototypes into products that will meet the customer's specifications for size, brightness, image quality and cost. Microvision has continued development work on these potential products in 2004.

Lumera

Lumera continues to develop WiFi antennas, electro-optical modulators and micro array platform chips that are based on its proprietary technology.

Results of Operations

THREE MONTHS ENDED JUNE 30, 2004 COMPARED TO THREE MONTHS ENDED JUNE 30, 2003

Contract Revenue

The Company earns contract revenue from performance on development contracts with United States government and commercial customers. Contract revenue in the three months ended June 30, 2004 decreased by approximately $2.6 million, or 59% to $1.8 million from $4.4 million in the same period in 2003. For the three months ended June 30, 2004, 55% of contract revenue was derived from performance on development contracts with the United States government and 45% from performance on development contracts with commercial customers. For the three months ended June 30, 2003, 62% of revenue was derived from performance on development contracts with the United States government, 38% from performance on development contracts with commercial customers. Contract revenue for Lumera was $288,000 and $396,000 for the three months ended June 30, 2004 and 2003, respectively.

In May, 2004, the Microvision entered into a $3.9 million contract modification with the U.S. Army’s Aviation Applied Technology Directorate to continue work on an advanced helmet mounted display and imaging system to be used in the Virtual Cockpit Optimization Program.

Contract revenue is dependant upon the timing and volume of contracts the Company has entered into and the availability of technical resources to perform work on the contracts. Contract revenue was lower during the three months ended June 30, 2004 than the same period in 2003, due to fewer new contracts being executed and lower backlog and the need to allocate resources to Nomad product support.

The Company believes that, as long as most of its revenue is earned from performance on development contracts, there may be a high degree of variability in revenue from quarter to quarter.

The backlog of development contracts at June 30, 2004 was $4.9 million, of which $4.3 million was attributable to Microvision. All development contracts in backlog are scheduled for completion and delivery during the next twelve months. The backlog of development contracts at June 30, 2003 was $3.4 million.

Product Revenue

Microvision earns product revenue from sales of Nomad and Flic. Product revenue in the three months ended June 30, 2004 increased by $440,000, or 299%, to $587,000 from $147,000 in the same period in 2003. For the three months ended June 30, 2004, 71% of product revenue was derived from the sales of Flic units and 29% from sales of Nomad units. For the three months ended June 30, 2003, 39% of product revenue was derived from the sales of Flic units and 61% from the sales of Nomad units.

Microvision believes that product revenue will increase from both Flic and Nomad sales as the products gain market acceptance. Quarterly revenue may vary substantially due to the timing of product orders from customers, production constraints, and raw material availability.

The backlog of product orders at June 30, 2004 was approximately $233,000, all of which is scheduled for delivery during the next twelve months.

Cost of Contract Revenue

Cost of contract revenue includes both the direct and allocated indirect costs of performing on development contracts. Direct costs include labor, materials and other costs incurred directly in performing on a contract. Indirect costs include labor and other costs associated with operating the Company’s research and development department and building the Company’s technical capabilities and capacity. Cost of contract revenue is determined both by the level of direct costs incurred on development contracts and by the level of indirect costs incurred in operating and building the Company’s technical capabilities and capacity. The cost of contract revenue can fluctuate substantially from period to period depending on the level of both the direct costs incurred in the performance of projects and the level of indirect costs incurred.

Cost of contract revenue for the three months ended June 30, 2004 decreased by $860,000 or 42% to $1.2 million from $2.1 million in the same period in 2003. Cost of contract revenue for Lumera was $188,000 and $185,000 for the three months ended June 30, 2004 and 2003, respectively. Total direct costs for the three months ended
Research and development overhead is allocated to both cost of contract revenue and research and development expense based on the proportion of direct labor cost incurred in cost of contract revenue and research and development, respectively. As a result of the lower direct labor cost in cost of revenue and a lower overhead rate for the three months ended June 30, 2004, approximately 46% less overhead was allocated to cost of revenue than in the same period in 2003.

Microvision expects that cost of contract revenue on an absolute dollar basis will increase in the future. This increase will likely result from additional development contract work that Microvision expects to perform. The cost of revenue as a percentage of revenue can fluctuate significantly from period to period, depending on the contract and contract cost mix and the levels of direct and indirect costs incurred. Microvision expects the cost of contract revenue, as a percentage of contract revenue, to fluctuate modestly over time.

Cost of Product Revenue. Cost of product revenue includes both the direct and allocated indirect costs of manufacturing Nomads and Flics sold to customers. Direct costs include labor, materials and other costs incurred directly in the manufacture of Flic and Nomad. Indirect costs include labor and other costs associated with operating Microvision’s manufacturing capabilities and capacity.

Cost of product revenue for the three months ended June 30, 2004 increased by $489,000 or 328% to $638,000 from $149,000 in the same period in 2003.

Microvision’s costs to produce Nomad units during the three months ended June 30, 2004 were substantially higher than product revenue. Microvision has classified production cost in excess of product revenue as research and development expense. Microvision does not expect Nomad production and the design and manufacturing processes to become sufficiently mature to support “commercial production” as described in SFAS No. 2 “Accounting for Research and Development Costs” until at least the fourth quarter of 2004.

At June 30, 2004, Microvision had Flic units that contain older versions of components or firmware in inventory. Microvision determined that these units will be upgraded to current standard or scrapped depending on the technical feasibility of upgrading the individual unit. In the three months ended June 30, 2004, Microvision recorded a write down of Flic inventory of $100,000 to reduce the Flics to their estimated value. This write down was included in cost of product revenue in the three months ended June 30, 2004.

Manufacturing overhead is allocated to inventory, cost of product revenue, cost of contract revenue, and research and development expense based on the proportion of direct material purchased for the respective activity.

Microvision expects that cost of product revenue on an absolute dollar basis will increase in the future. This increase will likely result from expected sales of commercial products. The cost of product revenue as a percentage of product revenue can fluctuate significantly from period to period, depending on the volume of direct materials purchased, the level of overhead expense and the product mix.

Research and Development Expense. Research and development expense consists of:

- Compensation related costs of employees and contractors engaged in internal research and product development activities,
- Research fees paid to the University of Washington under Sponsored Research Agreement,
- Laboratory operations, outsourced development and processing work,
- Fees and expenses related to patent applications, prosecution and protection,
- Nomad production cost in excess of Nomad revenue, respectively, and
- Other operating expenses.

Included in research and development expenses are costs incurred in acquiring and maintaining licenses.

Research and development expense in the three months ended June 30, 2004 decreased by $2.8 million, or 45% to $3.3 million from $6.1 million in the same period in 2003. Research and development expense for Lumera was ($963,000) and $1.8 million for the three months ended June 30, 2004 and 2003, respectively.

In April 2004, Lumera and the University of Washington entered into a fourth amendment to the Sponsored Research Agreement that requires payments of $125,000 for quarters ending March 31, 2004 and June 30, 2004 and eliminates a contingent payment of $2.0 million. For each of the quarters ending September 30, 2004 and December 31, 2004 Lumera is required to pay $250,000. The agreement will terminate in 2005 after payments of $375,000 are made in each of the quarters ending March 31, 2005 and June 30, 2005. Total payments under the Sponsored Research Agreement will be $5.8 million instead of the original $9.0 million.

Lumera recognizes research and development expense under the Sponsored Research Agreement on a straight line basis over the term of the agreement. At the time of the fourth amendment to the Sponsored Research Agreement, Lumera had recognized $6.5 million in expense related to the Sponsored Research Agreement. In April 2004, Lumera recorded a reduction in its liability and an offsetting reduction in expense of $2.4 million to reduce the cumulative expense recognized under the Sponsored Research Agreement to the expense incurred under the fourth amendment on a straight line basis. Lumera will continue to recognize approximately $325,000 per quarter in expense on the Sponsored research agreement until it expires in June 2005.

Research and development costs in 2003 include $645,000 for the closure of Microvision’s research and development facility in San Mateo, California. Microvision consolidated its research and development activities in Bothell, Washington in May 2003.

Microvision believes that a substantial level of continuing research and development expense will be required to complete development of a new version of Nomad and to develop additional commercial products using the scanned beam display technology. Accordingly, Microvision anticipates its level of research and development spending will continue to be substantial. These expenses could be incurred as a result of:

- Subcontracting work to development partners,
- Expanding and equipping in-house laboratories,
- Acquiring rights to additional technologies,
- Incurring related operating expenses, and
- Hiring additional technical and support personnel.
Marketing, General and Administrative Expense. Marketing, general and administrative expenses include compensation and support costs for sales, marketing, management and administrative staff, and for other general and administrative costs, including legal and accounting services, consultants and other operating expenses.

Marketing, general and administrative expenses in the three months ended June 30, 2004 increased by $805,000, or 18%, to $5.2 million from $4.4 million in the same period in 2003. Marketing general and administrative expense for Lumera was $751,000 and $280,000 for the three months ended June 30, 2004 and 2003, respectively.

Microvision’s increase is attributable to increased sales and marketing costs for the Nomad product. The increased costs have included salaries, travel and promotion costs directly related Nomad sales activity. Lumera’s increased costs include salaries and consulting fees related to preparing for its initial public offering.

Microvision expects marketing, general and administrative expenses to increase, commensurate with increases in revenue, in future periods as Microvision:

- Adds to its sales and marketing staff,
- Makes additional investments in sales and marketing activities, and
- Increases the level of corporate and administrative activity.

Non-Cash Compensation Expense. Non-cash compensation expense in the three months ended June 30, 2004 increased $481,000, or 106%, to $933,000 from $452,000 in the same period in 2003. During the three months ended March 31, 2004, Lumera granted options to purchase 415,000 shares of Class A common stock to Lumera employees and directors with a weighted-average exercise price of $2.00. Lumera determined that the fair market value of its common stock was $3.35 per share on the grant date. The Company recorded an aggregate charge of $216,000 of non-cash compensation expense during the three months ended March 31, 2004 related to these grants as the exercise price was deemed to be below the fair value of the common stock. In addition the Company recorded amortization of deferred stock-based compensation of $278,000 during the three months ended June 30, 2004 related to Lumera’s option grants to employees and its Board of Directors. In July 2004, Lumera revised its estimate of the fair value of its common stock. This revision resulted in an adjustment to Lumera stock based compensation charge during the first quarter of 2004 of $305,000. The Company recorded this revision to the consolidated non-cash compensation expense account during the second quarter of 2004. The net impact to the consolidated net loss for the three months ended June 30, 2004 was to increase the net loss by $39,000.

The following table shows the major components of non-cash compensation expense for the three months ended June 30, 2004 and 2003, respectively.

<table>
<thead>
<tr>
<th>Description</th>
<th>Three months ended June 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2004</td>
</tr>
<tr>
<td>Lumera stock issued to the University of Washington</td>
<td>$</td>
</tr>
<tr>
<td>Microvision and Lumera securities issued to third parties</td>
<td>375,000</td>
</tr>
<tr>
<td>Microvision and Lumera stock options issued to employees</td>
<td>216,000</td>
</tr>
<tr>
<td>Microvision and Lumera options issued to Non-Management Directors</td>
<td>342,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>933,000</strong></td>
</tr>
</tbody>
</table>

At June 30, 2004, Microvision and Lumera had $642,000 and $1,043,000 respectively, of unamortized non-cash compensation expense that will be amortized over the next three years.

Interest Income and Expense. Interest income in the three months ended June 30, 2004 decreased by $12,000, or 13%, to $79,000 from $91,000 in the same period in 2003. This decrease resulted primarily from lower average cash and investment securities balances in the three months ended June 30, 2004 than the average cash and investment securities balances in the same period of the prior year.

Interest expense increased due to interest expense on Lumera’s $2.3 million promissory notes.

Results of Operations

SIX MONTHS ENDED JUNE 30, 2004 COMPARED TO SIX MONTHS ENDED JUNE 30, 2003

Contract Revenue. Contract revenue in the six months ended June 30, 2004 decreased by approximately $3.7 million, or 47%, to $4.1 million from $7.8 million in the same period in 2003. For the six months ended June 30, 2004, 54% of contract revenue was derived from performance on development contracts with the United States government and 46% from performance on development contracts with commercial customers. For the six months ended June 30, 2003, 54% of revenue was derived from performance on development contracts with the United States government, 46% from performance on development contracts with commercial customers. Contract revenue for Lumera was $604,000 and $765,000 for the six months ended June 30, 2004 and 2003, respectively.

In May 2004, the Microvision entered into a $3.9 million contract modification with the U.S. Army’s Aviation Applied Technology Directorate to continue work on an advanced helmet mounted display and imaging system to be used in the Virtual Cockpit Optimization Program.

Contract revenue is dependant upon the timing and volume of contracts the Company has entered into and the availability of technical resources to perform work on the contracts. Contract revenue was lower during the six months ended June 30, 2004 than the same period in 2003, due to fewer new contracts being executed and lower backlog and the need to allocate resources to Nomad product support.

Product Revenue. Product revenue in the six months ended June 30, 2004 increased by $1.0 million, or 349%, to $1.3 million from $281,000 in the same period in 2003. For the six months ended June 30, 2004, 86% of product revenue was derived from the sales of Flic units and 14% form the sales of Nomad units, respectively. For the six months ended June 30, 2003, 46% of product revenue was derived from the sales of Flic units and 54% from the sales of Nomad units, respectively.

Microvision believes that product revenue will increase from both Flic and Nomad sales as the products gain market acceptance. Quarterly revenue may vary substantially due to the timing of product orders from customers, production constraints, and raw material availability.

Cost of Contract Revenue. Cost of contract revenue for the six months ended June 30, 2004 decreased by $959,000 or 29% to $2.4 million from $3.4 million in the same period in 2003. Cost of contract revenue for Lumera was $382,000 and $383,000 for the six months ended June 30, 2004 and 2003, respectively. Total direct costs for the six months ended June 30, 2004 decreased by 27% from the same period in 2003. The total direct labor component of direct costs for the six months ended June 30, 2004 decreased by 33% from the same period in 2003. The Company experienced unplanned technical difficulties on one project as a result of the difficulties more direct cost than
plan was incurred in completing the project resulting in a lower gross margin during the three months ended June 30, 2004 than the same period in 2003.

Research and development overhead is allocated to both cost of contract revenue and research and development expense based on the proportion of direct labor cost incurred in cost of contract revenue and research and development, respectively. As a result of the lower direct labor cost in cost of revenue and a lower overhead rate for the six months ended June 30, 2004, approximately 30% less overhead was allocated to cost of revenue than in the same period in 2003.

Cost of Product Revenue. Cost of product revenue for the six months ended June 30, 2004 increased by $1.0 million or 413% to $1.3 million from $254,000 in the same period in 2003.

Microvision’s costs to produce Nomad units during the three months ended June 30, 2004 were substantially higher than product revenue. Microvision has classified production cost in excess of product revenue as research and development expense. The Company does not expect Nomad production and the design and manufacturing processes to become sufficiently mature to support “commercial production” as described in SFAS No. 2 “Accounting for Research and Development Costs” until at least the fourth quarter of 2004.

Research and Development Expense. Research and development expense in the six months ended June 30, 2004 decreased by $4.9 million, or 38% to $8.0 million from $12.9 million in the same period in 2003. Research and development expense for Lumera was $504,000 and $3,537,000 for the six months ended June 30, 2004 and 2003, respectively.

In April 2004, Lumera and the University of Washington entered into a fourth amendment to the Sponsored Research Agreement that requires payments of $125,000 for quarters ending March 31, 2004 and June 30, 2004 and eliminates the contingent payment of $2.0 million. For each of the quarters ending September 30, 2004 and December 31, 2004 Lumera is required to pay $250,000. The agreement will terminate in 2005 after payments of $375,000 are made in quarters ending March 31, 2005 and June 30, 2005. Total payments under the Sponsored Research Agreement will be $5.8 million instead of the original $9.0 million. Lumera recognizes research and development expense under the Sponsored Research Agreement on a straight line basis over the term of the agreement. At the time of the fourth amendment to the Sponsored Research Agreement, Lumera had recognized $6.5 million in expense related to the Sponsored Research Agreement. In April 2004, Lumera recorded a reduction in its liability and an offsetting reduction in expense of $2.4 million to reduce the cumulative expense recognized under the Sponsored Research Agreement to the expense incurred under the fourth amendment on a straight line basis. Lumera will continue to recognize approximately $325,000 per quarter in expense on the Sponsored research agreement until it expires in June 2005.

Research and development costs in 2003 include $645,000 for the closure of Microvision’s research and development facility in San Mateo, California. Microvision consolidated its research and development activities in Bothell, Washington in May 2003.

Marketing, General and Administrative Expense. Marketing, general and administrative expenses in the six months ended June 30, 2004 increased by $1.1 million, or 13%, to $9.8 million from $8.7 million in the same period in 2003. The increase is attributable to increased sales and marketing costs for the Nomad product. The increased costs have included salaries, travel and promotion costs directly related Nomad sales activity. Marketing general and administrative expense for Lumera was $1.2 million and $620,000 for the six months ended June 30, 2004 and 2003, respectively.

Non-Cash Compensation Expense. Non-cash compensation expense in the six months ended June 30, 2004 increased by $699,000 or 76%, to $1.6 million from $917,000 in the same period in 2003.

During the six months ended June 30, 2004, the Lumera granted options to purchase 415,000 shares of Class A common stock to Lumera employees and directors with a weighted-average exercise price of $2.00. Lumera determined that the fair market value of its common stock was $3.35 per share on the grant date. Lumera recorded an aggregate charge of $216,000 of non-cash compensation expense during the three months ended March 31, 2004 related to these grants as the exercise price was deemed to be below the fair value of the common stock. In addition the Company recorded amortization of deferred stock-based compensation of $278,000 during the three months ended June 30, 2004 related to Lumera’s option grants to employees and its Board of Directors. In July 2004, Lumera revised its estimate of the fair value of its common stock. This revision resulted in an adjustment to Lumera’s stock based compensation charge during the first quarter of 2004.

The revision resulted in an adjustment to Lumera’s stock based compensation charge during the first quarter of 2004 of $305,000. The Company recorded this revision to the consolidated non-cash compensation expense amount during the second quarter of 2004. The net impact to the consolidated net loss for the three months ended June 30, 2004 was to increase the net loss by $39,000. The adjustment had no impact on the Company’s consolidated net loss for the six months ended June 30, 2004.

The following table shows the major components of non-cash compensation expense for the six months ended June 30, 2004 and 2003, respectively.

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumera stock issued to the University of Washington</td>
<td>$159,000</td>
<td>$502,000</td>
</tr>
<tr>
<td>Microvision and Lumera securities issued to third parties</td>
<td>659,000</td>
<td>342,000</td>
</tr>
<tr>
<td>Microvision and Lumera stock options issued to employees</td>
<td>253,000</td>
<td>73,000</td>
</tr>
<tr>
<td>Microvision and Lumera stock and options issued to Non-Management Directors</td>
<td>545,000</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$1,616,000</strong></td>
<td><strong>$917,000</strong></td>
</tr>
</tbody>
</table>

Interest Income and Expense. Interest income in the six months ended June 30, 2004 decreased by $33,000, or 15%, to $181,000 from $214,000 in the same period in 2003. This decrease resulted primarily from lower average cash and investment securities balances in the six months ended June 30, 2004 than the average cash and investment securities balances in the same period of the prior year.

Interest expense increased due to interest expense on Lumera’s $2.3 million promissory notes.

Liquidity and Capital Resources

The Company has funded operations to date primarily through the sale of common stock, convertible preferred stock, warrants and, to a lesser extent, from development contract revenues and product sales. At June 30, 2004, Microvision had $6.0 million and Lumera had $657,000 in cash, cash equivalents and investment securities.

Cash used in operating activities totaled $17.6 million during the six months ended June 30, 2004, compared to $14.4 million during the same period in 2003. Cash used in operating activities for each period resulted primarily from the net loss for the period.

- “Inventory” increased by $2.5 million to $2.8 million at June 30, 2004 from $331,000 at December 31, 2003. The increase was primarily attributable to purchases of...
Nomad inventory. The Company made commitments to purchase minimum quantities of inventory at the start of Nomad production. Microvision has taken delivery of most of this inventory and plans for inventory as a percent of revenue to decline as the nomad product revenue is expected to increase. The Company values inventory at the lower of cost or market with cost determined on a weighted average cost basis. The following table shows the composition of the inventory at June 30, 2004 and December 31, 2003, respectively.

<table>
<thead>
<tr>
<th></th>
<th>June 30 2004</th>
<th>December 31, 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raw materials</td>
<td>$1,700,000</td>
<td>$98,000</td>
</tr>
<tr>
<td>Work in process</td>
<td>112,000</td>
<td></td>
</tr>
<tr>
<td>Finished goods</td>
<td>1,009,000</td>
<td>233,000</td>
</tr>
<tr>
<td></td>
<td>$2,821,000</td>
<td>$331,000</td>
</tr>
</tbody>
</table>

- “Account Payable” increased $2.1 million to $3.3 million at June 30, 2004 from $1.2 million at December 31, 2003. The increase in Accounts Payable is directly attributable to the increase in inventory. The Company has thirty day payment terms with most of its vendors.

- “Current portion of notes payable” increased $2.4 million at June 30, 2004 from $0 at December 31, 2003. The increase is attributable to Lumera’s issuance of $2.3 million in convertible promissory notes in April 2004. The notes accrue interest at a rate of 6.5% per annum and are payable on demand upon the closing of an underwritten public offering of Lumera’s common stock. Lumera completed an initial public offering in July 2004. The principal amount and any accrued but unpaid interest in respect of each note is convertible at any time, at the option of the holder, into shares of Lumera’s Class A common stock. The conversion price is $6.60 per share of common stock. In connection with the sale of these convertible notes, Lumera also issued warrants to purchase shares of common stock. The number of shares is based on a formula based on the exercise price of the warrant and the face amount of the holder’s convertible note. The exercise price of the warrants is $7.20 per share. All of the warrants are exercisable on the date of grant and expire in April 2009. The value of the warrants granted was estimated to be approximately $344,000 using the Black Scholes option pricing model. The relative fair value of the warrants of $299,000 will be treated as a debt issuance cost and is being amortized to interest expense over the one year term of the convertible notes

- “Research liability” decreased $1.9 million to $78,000 at June 30, 2004 from $1.9 million at December 31, 2003. In April 2004, Lumera and the University of Washington entered into a fourth amendment to the Sponsored Research Agreement that requires payments of $125,000 for the quarters ending March 31, 2004 and June 30, 2004 and eliminates a contingent payment of $2.0 million. For each of the quarters ending September 30, 2004 and December 31, 2004 Lumera is required to pay $250,000. The agreement will terminate in 2005 after payments of $375,000 are made in each of the quarters ending March 31, 2005 and June 30, 2005. Total payments under the Sponsored Research Agreement will be $5.8 million instead of the original $9.0 million. Lumera recognizes research and development expense under the Sponsored Research Agreement on a straight line basis over the remaining term of the agreement. At the time of the fourth amendment to the Sponsored Research Agreement, Lumera had recognized $6.5 million in cumulative expense related to the Sponsored Research Agreement. In April 2004, Lumera recorded a reduction in its liability and an offsetting reduction in expense of $2.4 million to reduce the cumulative expense recognized under the Sponsored Research Agreement to the expense incurred under the fourth amendment on a straight line basis. Lumera will continue to recognize approximately $325,000 per quarter in expense on the Sponsored research agreement until it expires in June 2005.

Cash provided by investing activities totaled $7.0 million during the six months ended June 30, 2004, compared to $2.2 million during the same period of 2003. During the six months ended June 30, 2004, the Company had net sales of investment securities of $7.5 million compared to $2.8 million during the same period in 2003. The proceeds from the sales of investment securities were used to fund the Company’s operations.

The Company used cash of $585,000 for capital expenditures during the six months ended June 30, 2004, compared to $628,000 during the same period in 2003. Capital expenditures include leasehold improvements to leased office space and computer hardware and software, laboratory equipment and furniture and fixtures to support operations.

Cash provided by financing activities totaled $3.1 million during the six months ended June 30, 2004, compared to $11.5 million during the same period in 2003.

On March 12, 2004 Lumera raised $500,000, before issuance costs, from the sale of 250,000 shares of Series B convertible preferred stock to a group of private investors. Microvision did not participate in the offering.

In April 2004, Lumera raised $2.3 million from the issuance of convertible promissory notes. The notes accrue interest at a rate of 6.5% per annum and are payable on demand upon the closing of an underwritten public offering of Lumera’s common stock. Lumera completed an initial public offering in July 2004. The principal amount and any accrued but unpaid interest in respect of each note is convertible at any time, at the option of the holder, into shares of Lumera’s Class A common stock. The conversion price is $6.60 per share of common stock. In connection with the sale of these convertible notes, Lumera also issued warrants to purchase shares of common stock. The number of shares is based on a formula based on the exercise price of the warrant and the face amount of the holder’s convertible note. The exercise price of the warrants is $7.20 per share. All of the warrants are exercisable on the date of grant and expire in April 2009. The value of the warrants granted was estimated to be approximately $344,000 using the Black Scholes option pricing model. The relative fair value of the warrants of $299,000 will be treated as a debt issuance cost and is being amortized to interest expense over the one year term of the convertible notes

In July 2004 Lumera raised $42.0 million before issuance costs of $4.3 million from an initial public offering of its common stock. In connection with the offering of its common stock, all Lumera Series A and Series B Preferred Stock was converted to Lumera common stock. Immediately after the offering Microvision owns 5,434,000 shares or 33% of the common stock of Lumera. As a result of the change in ownership percentage, Microvision will change the method of accounting for its investment in Lumera to the equity method. Microvision expects to record a non-cash change in interest gain of approximately $13.0 million during the third quarter as a result of the public offering. In connection with the Lumera initial public offering, Microvision entered into a six month lock-up agreement. During the lock-up period, Microvision cannot sell or pledge as collateral its shares of Lumera stock.

Future operating expenditures and capital requirements will depend on numerous factors, including the following:

- The progress of research and development programs,
- The progress in commercialization activities and arrangements,
- The cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights,
were to trade in the over-the-counter market, an investor would find it more difficult to dispose of, or to obtain accurate quotations for the price of, the common stock. A
in the over-the-counter market on an electronic bulletin board established for unlisted securities or directly through market makers in our common stock. If our common stock
reduce the liquidity for our common stock. If our common stock were not listed on the SmallCap Market or an exchange, trading of our common stock would be conducted
Nasdaq’s listing maintenance standards, our common stock could be delisted from the Nasdaq National Market. If our common stock were delisted, we likely would seek to
It may become more difficult to sell our stock in the public market.

We have a history of operating losses and expect to incur significant losses in the future.
We have had substantial losses since our inception and we anticipate an operating loss at least through the year ending December 31, 2004. We cannot assure you that we will ever become or remain profitable.

• As of June 30, 2004, we had an accumulated deficit of $169.5 million.
• We incurred consolidated net losses of $100.9 million from inception through 2001, $27.2 million in 2002, $26.2 million in 2003, and $15.2 million for the six months ended June 30, 2004.

The likelihood of our success must be considered in light of the expenses, difficulties and delays frequently encountered by companies formed to develop and market new technologies. In particular, our operations to date have focused primarily on research and development of the scanned beam technology and development of demonstration units. We introduced our first two commercial products during 2002. We are unable to accurately estimate future revenues and operating expenses based upon historical performance.

We cannot be certain that we will succeed in obtaining additional development contracts or that we will be able to obtain substantial customer orders for our products. In light of these factors, we expect to continue to incur substantial losses and negative cash flow at least through Mid 2005 and likely thereafter. We cannot be certain that we will achieve positive cash flow at any time in the future.

We will require additional capital to continue to fund our operations and to implement our business plan. If we do not obtain additional capital, we may be required to limit our operations substantially. Raising additional capital may dilute the value of current shareholders’ shares.

Based on our current operating plan and budgeted cash requirements, we believe that we can fund our operations through September 2004. We will require additional capital to continue to fund our operations, including to:

• Further develop the scanned beam and polymer materials technologies,
• Add manufacturing capacity,
• Develop and protect our intellectual property rights, and
• Fund long-term business development opportunities.

We will require additional capital prior to September 30, 2004. If revenues are less than we anticipate, if the level and mix of revenues vary from anticipated amounts and allocations or if expenses exceed the amounts budgeted, we may require additional capital earlier to further the development of our technologies, for expenses associated with product development, and to respond to competitive pressures or to meet unanticipated development difficulties. In addition, our operating plan provides for the development of strategic relationships with systems and equipment manufacturers that may require additional investments by us. Additional financing may not be available to us or, if available, may not be available on terms acceptable to us on a timely basis. If adequate funds are not available to satisfy either short-term or long-term capital requirements, we may be required to limit our operations substantially. Our capital requirements will depend on many factors, including, but not limited to, the rate at which we can, directly or through arrangements with original equipment manufacturers, introduce products incorporating the scanned beam and optical material technologies and the market acceptance and competitive position of such products. Raising additional capital may involve issuing securities with rights and preferences that are senior to our common stock and may dilute the value of current shareholders’ shares.

We cannot be certain that the scanned beam technology or products incorporating this technology will achieve market acceptance. If the scanned beam technology does not achieve market acceptance, our revenues may not grow.
Our success will depend in part on customer acceptance of the scanned beam technology. The scanned beam technology may not be accepted by manufacturers who use display technologies in their products, by systems integrators who incorporate our products into their products or by consumers of these products. To be accepted, the scanned beam technology must meet the expectations of our potential customers in the defense, industrial, medical and consumer markets. If our technology fails to achieve market acceptance, we may not be able to continue to develop the scanned beam technology.

It may become more difficult to sell our stock in the public market.
Our common stock is listed for quotation on the Nasdaq National Market. To keep our listing on this market, we must meet Nasdaq’s listing maintenance standards. If we are unable to continue to meet Nasdaq’s listing maintenance standards, our common stock could be delisted from the Nasdaq National Market. If our common stock were delisted, we likely would seek to list the common stock on the Nasdaq SmallCap Market, the American Stock Exchange or on a regional stock exchange. Listing on such other market or exchange could reduce the liquidity for our common stock. If our common stock were not listed on the SmallCap Market or an exchange, trading of our common stock would be conducted in the over-the-counter market on an electronic bulletin board established for unlisted securities or directly through market makers in our common stock. If our common stock were to trade in the over-the-counter market, an investor would find it more difficult to dispose of, or to obtain accurate quotations for the price of, the common stock. A
delisting from the Nasdaq National Market and failure to obtain listing on such other market or exchange would subject our securities to so-called penny stock rules that impose additional sales practice and market-making requirements on broker-dealers who sell or make a market in such securities. Consequently, removal from the Nasdaq National Market and failure to obtain listing on another market or exchange could affect the ability or willingness of broker-dealers to sell or make a market in our common stock and the ability of purchasers of our common stock to sell their securities in the secondary market. In addition, when the market price of our common stock is less than $5.00 per share, we become subject to penny stock rules even if our common stock is still listed on the Nasdaq National Market. While the penny stock rules should not affect the quotation of our common stock on the Nasdaq National Market, these rules may further limit the market liquidity of our common stock and the ability of investors to sell our common stock in the secondary market. During the second, third and fourth quarters of 2002 and the first and second quarter of 2003, the market price of our stock traded below $5.00 per share. On August 6, 2004 the closing price of our stock was $4.26.

Our lack of the financial and technical resources relative to our competitors may limit our revenues, potential profits and overall market share.

Our current products and potential future products will compete with established manufacturers of existing products and companies developing new technologies. Many of our competitors have substantially greater financial, technical and other resources than we. Because of their greater resources, our competitors may develop products or technologies that are superior to our own. The introduction of superior competing products or technologies could result in reduced revenues, lower margins or loss of market share, any of which could reduce the value of our business.

We may not be able to keep up with rapid technological change and our financial results may suffer.

The information display industry has been characterized by rapidly changing technology, accelerated product obsolescence and continuously evolving industry standards. Our success will depend upon our ability to further develop the scanned beam technology and to cost effectively introduce new products and features in a timely manner to meet evolving customer requirements and compete with competitors’ product advances.

We may not succeed in these efforts because of:

• delays in product development,
• lack of market acceptance for our products, or
• lack of funds to invest in product development and marketing.

The occurrence of any of the above factors could result in decreased revenues and market share.

We could face lawsuits related to our use of the scanned beam technology or other technologies. Defending these suits would be costly and time consuming. An adverse outcome in any such matter could limit our ability to commercialize our technology and products, reduce our revenues and increase our operating expenses.

We are aware of several patents held by third parties that relate to certain aspects of scanned beam displays and image capture products. These patents could be used as a basis to challenge the validity, limit the scope or limit our ability to obtain additional or broader patent rights of our patents or patents we have licensed. A successful challenge to the validity of our patents or patents we have licensed could limit our ability to commercialize the scanned beam technology and other technologies and, consequently, materially reduce our revenues. Moreover, we cannot be certain that patent holders or other third parties will not claim infringement by us with respect to current and future technology. Because U.S. patent applications are held and examined in secrecy, it is also possible that presently pending U.S. applications will eventually be issued with claims that will be infringed by our products or the scanned beam technology. The defense and prosecution of a patent suit would be costly and time consuming, even if the outcome were ultimately favorable to us. An adverse outcome in the defense of a patent suit could subject us to significant cost, to require others and us to cease selling products that incorporate scanned beam technology, to cease licensing scanned beam technology or to require disputed rights to be licensed from third parties. Such licenses, if available, would increase our operating expenses. Moreover, if claims of infringement are asserted against our future co-development partners or customers, those partners or customers may seek indemnification from us for damages or expenses they incur.

Our planned future products are dependent on advances in technology by other companies.

We rely on and will continue to rely on technologies, such as light sources and optical components that are developed and produced by other companies. The commercial success of certain of our planned future products will depend in part on advances in these and other technologies by other companies. Due to the current business environment, many companies that are developing new technologies are reducing expenditures on research and development. This may delay the development and commercialization of components we would use to manufacture certain of our planned future products.

Our products may be subject to future health and safety regulations that could increase our development and production costs.

Products incorporating scanned beam display technology could become subject to new health and safety regulations that would reduce our ability to commercialize the scanned beam display technology. Compliance with any such new regulations would likely increase our cost to develop and produce products using the scanned beam display technology and adversely affect our financial results.

If we cannot manufacture products at competitive prices, our financial results will be adversely affected.

To date, we have produced limited quantities of Nomad and Flic, and demonstration units for research, development and demonstration purposes. The cost per unit for these units currently exceeds the level at which we could expect to profitably sell these products. If we cannot lower our cost of production, we may face increased demands on our financial resources, possibly requiring additional equity and/or debt financing to sustain our business operations.

Our future growth will suffer if we do not achieve sufficient market acceptance of our products to compete effectively.

Our success depends, in part, on our ability to gain acceptance of our current and future products by a large number of customers. Achieving market-based acceptance for our products will require marketing efforts and the expenditure of financial and other resources to create product awareness and demand by potential customers. We may be unable to offer products consistently or at all that compete effectively with products of others on the basis of price or performance. Failure to achieve broad acceptance of our products by potential customers and to effectively compete would have a material adverse effect on our operating results.

Because we plan to continue using foreign contract manufacturers, our operating results could be harmed by economic, political, regulatory and other factors existing in foreign countries.
We currently use a contract manufacturer in Asia to manufacture Flic, and we plan to continue using foreign manufacturers to manufacture some of our products where appropriate. These international operations are subject to inherent risks, which may adversely affect us, including:

- political and economic instability;
- high levels of inflation, historically the case in a number of countries in Asia;
- burdens and costs of compliance with a variety of foreign laws;
- foreign taxes; and
- changes in tariff rates or other trade and monetary policies.

If we experience delays or failures in developing commercially viable products, we may have lower revenues.

We began production of Nomad, our first commercial product, in December 2001. In September 2002, we introduced Flic, our second commercial product. In addition, we have developed demonstration units incorporating the scanned beam technology, and demonstration units have been built using the polymer materials technology. However, we must undertake additional research, development and testing before we are able to develop additional products for commercial sale. Product development delays by us or our potential product development partners, or the inability to enter into relationships with these partners, may delay or prevent us from introducing products for commercial sale.

If we cannot supply products in commercial quantities, we will not achieve commercial success.

We are developing our capability to manufacture products in commercial quantities. Our success depends in part on our ability to provide our components and future products in commercial quantities at competitive prices. Accordingly, we will be required to obtain access, through business partners or contract manufacturers, to manufacturing capacity and processes for the commercial production of our expected future products. We cannot be certain that we will successfully obtain access to sufficient manufacturing resources. Future manufacturing limitations of our suppliers could result in a limitation on the number of products incorporating our technology that we are able to produce.

If our licensors and we are unable to obtain effective intellectual property protection for our products and technology, we may be unable to compete with other companies.

Intellectual property protection for our products is important and uncertain. If we do not obtain effective intellectual property protection for our products, processes and technology, we may be subject to increased competition. Our commercial success will depend in part on our ability to protect the proprietary nature of the scanned beam display and other key technologies by securing valid and enforceable patents and effectively maintaining unpatented technology as trade secrets. We try to protect our proprietary technology by seeking to obtain United States and foreign patents in our name, or licenses to third-party patents, related to proprietary technology, inventions, and improvements that may be important to the development of our business. However, our patent position and the patent position of the University of Washington and other licensors involves complex legal and factual questions. The standards that the United States Patent and Trademark Office and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Additionally, the scope of patents are subject to interpretation by courts and their validity can be subject to challenges and defenses, including challenges and defenses based on the existence of prior art. Consequently, we cannot be certain as to the extent to which we will be able to obtain patents for our new products and technology or the extent to which the patents that we already own or license from others protect our products and technology. Reduction in scope of protection or invalidation of our licensed or owned patents, or our inability to obtain new patents, may enable other companies to develop products that compete with ours on the basis of the same or similar technology.

We also rely on the law of trade secrets to protect unpatented know-how and technology to maintain our competitive position. We try to protect this know-how and technology by limiting access to the trade secrets to those of our employees contractors and partners with a need to know such information and by entering into confidentiality agreements with parties that have access to it, such as our employees, consultants and business partners. Any of these parties could breach the agreements and disclose our trade secrets or confidential information, or our competitors might learn of the information in some other way. If any trade secret not protected by a patent were to be disclosed to or independently developed by a competitor, our competitive position could be materially harmed.

We could be exposed to significant product liability claims that could be time-consuming and costly, divert management attention and adversely affect our ability to obtain and maintain insurance coverage.

We may be subject to product liability claims if any of our product applications are alleged to be defective or cause harmful effects. For example, because our scanned beam displays are designed to scan a low power beam of colored light into the user’s eye, the testing, manufacture, marketing and sale of these products involve an inherent risk that product liability claims will be asserted against us. Product liability claims or other claims related to our products, regardless of their outcome, could require us to spend significant time and money in litigation, divert management time and attention, require us to pay significant damages, harm our reputation or hinder acceptance of our products. Any successful product liability claim may prevent us from obtaining adequate product liability insurance in the future on commercially desirable or reasonable terms. An inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of our products.

We rely heavily on a limited number of development contracts with the U.S. government, which are subject to immediate termination by the government for convenience at any time, and the termination of one or more of these contracts could have a material adverse impact on our operations.

During the first six months of 2004 and for the years 2003 and 2002, 42%, 49% and 83%, respectively, of our consolidated revenue was derived from performance on a limited number of development contracts with the U.S. government. Therefore, any significant disruption or deterioration of our relationship with the U.S. government would significantly reduce our revenues. Our government programs must compete with programs managed by other contractors for limited amounts and uncertain levels of funding. The total amount and levels of funding are susceptible to significant fluctuations on a year-to-year basis. Our competitors continuously engage in efforts to expand their business relationships with the government and are likely to continue these efforts in the future. Our contracts with the government are subject to immediate termination by the government for convenience at any time. The government may choose to use contractors with competing display technologies or it may decide to discontinue any of our programs altogether. In addition, those development contracts that we do obtain require ongoing compliance with applicable government regulations. Termination of our development contracts, a shift in government spending to other programs in which we are not involved, a reduction in government spending generally, or our failure to meet applicable government regulations could have severe consequences for our results of operations.

Our products have long sales cycles, which make it difficult to plan our expenses and forecast our revenues.
We have a lengthy sales cycle that involves numerous steps including discussion of a product application, exploring the technical feasibility of a proposed product, evaluating the costs of manufacturing a product and manufacturing or contracting out the manufacturing of the product. Our long sales cycle, which can last several years, makes it difficult to predict the quarter in which sales will occur. Delays in sales could cause significant variability in our revenues and operating results for any particular quarterly period.

**Our exploratory arrangements may not lead to products that will be profitable.**

Our developmental contracts, including our relationships with parties such as the U.S. government, Canon, BMW and Volkswagen of America, are exploratory in nature and are intended to develop new types of products for new applications. These efforts may prove unsuccessful, and these relationships may not result in the development of products that will be profitable.

**Our revenues are highly sensitive to developments in the defense and aerospace industries.**

Our revenues to date have been derived principally from product development research relating to defense applications of the scanned beam display technology. We believe that development programs and sales of potential products in this market will represent a significant portion of our future revenues. Developments that adversely affect the defense sector, including delays in government funding and a general economic downturn, could cause our revenues to decline substantially.

**Our Virtual Retinal Display technology depends on our licenses from the University of Washington. If we lose our rights under the licenses, our operations would be adversely affected.**

We have acquired the exclusive rights to the Virtual Retinal Display under a license from the University of Washington. The license expires upon expiration of the last of the University of Washington’s patents that relate to this technology, which we currently anticipate will not occur until after 2011. We could lose our exclusivity under the license if we fail to respond to an infringement action or fail to use our best efforts to commercialize the licensed technology. In addition, the University of Washington may terminate the license upon our breach and has the right to consent to all sublicense arrangements. If we were to lose our rights under the license, or if the University of Washington were to refuse to consent to future sublicenses, we would lose a competitive advantage in the market, and may even lose the ability to commercialize our products completely. Either of these results could substantially decrease our revenues.

**We are dependent on third parties in order to develop, manufacture, sell and market our products.**

Our strategy for commercializing the scanned beam technology and products incorporating the scanned beam technology includes entering into cooperative development, sales and marketing arrangements with corporate partners, original equipment manufacturers and other third parties. We cannot be certain that we will be able to negotiate arrangements on acceptable terms, if at all, or that these arrangements will be successful in yielding commercially viable products. If we cannot establish these arrangements, we would require additional capital to undertake such activities on our own and would require extensive manufacturing, sales and marketing expertise that we do not currently possess and that may be difficult to obtain. In addition, we could encounter significant delays in introducing the scanned beam technology or find that the development, manufacture or sale of products incorporating the scanned beam technology would not be feasible. To the extent that we enter into cooperative development, sales and marketing or other joint venture arrangements, our revenues will depend upon the performance of third parties. We cannot be certain that any such arrangements will be successful.

**Loss of any of our key personnel could have a negative effect on the operation of our business.**

Our success depends on our executive officers and other key personnel and on the ability to attract and retain qualified new personnel. Achievement of our business objectives will require substantial additional expertise in the areas of sales and marketing, research and product development and manufacturing.

**Competition for qualified personnel in these fields is intense, and the inability to attract and retain additional highly skilled personnel, or the loss of key personnel, could reduce our revenues and adversely affect our business.**

**Our quarterly performance may vary substantially and this variance, as well as general market conditions, may cause our stock price to fluctuate greatly and potentially expose us to litigation.**

Our revenues to date have been generated from a limited number of development contracts with U.S. government entities and commercial partners. Our quarterly operating results may vary significantly based on:

- reductions or delays in funding of development programs involving new information display technologies by the U.S. government or our current or prospective commercial partners;
- changes in evaluations and recommendations by any securities analysts following our stock or our industry generally;
- announcements by other companies in our industry;
- changes in business or regulatory conditions;
- announcements or implementation by our competitors of technological innovations or new products;
- the status of particular development programs and the timing of performance under specific development agreements;
- economic and stock market conditions; or
- other factors unrelated to our company or industry.

In one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors and the trading price of our common stock may decline as a consequence. In addition, following periods of volatility in the market price of a company’s securities, shareholders often have instituted securities class action litigation against that company. If we become involved in a class action suit, it could divert the attention of management, and, if adversely determined, could require us to pay significant damages.

**If we fail to manage expansion effectively, our revenue and expenses could be adversely affected.**

Our ability to successfully offer products and implement our business plan in a rapidly evolving market requires an effective planning and management process. We have significantly expanded the scope of our operations. The growth in business and relationships with customers and other third parties has placed, and will continue to place, a significant strain on our management systems and resources. We will need to continue to improve our financial and managerial controls, reporting systems and procedures and
If the value of our investment in Lumera decreases, our income will be adversely affected.

A significant portion of our assets include an investment in Lumera. Lumera’s stock price is subject to fluctuation and may decrease, lowering the value of our investment. We also hold approximately 33% of Lumera’s common stock. Since we own a large percentage of Lumera’s common stock, if an active market does not develop or is not sustained, it may be difficult for us to sell our shares of common stock at an attractive price or at all. In connection with the Lumera initial public offering we entered into a six month lock-up agreement. During the lock-up period we cannot sell or pledge as collateral our shares of Lumera stock. The likelihood of Lumera’s success, and the value of the common stock we hold, must be considered in light of the risks frequently encountered by early stage companies, especially those formed to develop and market new technologies. These risks include Lumera’s potential inability to establish product sales and marketing capabilities; to establish and maintain markets for their potential products; and to continue to develop and upgrade their technologies to keep pace with changes in technology and the growth of markets using polymer materials. If Lumera is unsuccessful in meeting these challenges, its stock price, and the value of our investment, could decrease.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Substantially all of the Company’s cash equivalents and investment securities are at fixed interest rates and, as such, the fair value of these instruments is affected by changes in market interest rates. Due to the generally short-term maturities of these investment securities, Microvision believes that the market risk arising from its holdings of these financial instruments is not material. A one-percent change in market interest rates would have approximately a $6,000 impact on the fair value of the investment securities.

The Company’s investment policy restricts investments to ensure principal preservation and liquidity. The Company invests cash that it expects to use within approximately sixty days in U.S. treasury-backed instruments. The Company invests cash in excess of approximately sixty days of its requirements in high quality investment securities. The investment securities portfolio is limited to U.S. government and U.S. government agency debt securities and other high-grade securities generally with maturities of three years or less.

The weighted average maturities of cash equivalents and investment securities available-for-sale as of June 30, 2004, are as follows (dollar amounts in thousands):

<table>
<thead>
<tr>
<th>Maturity</th>
<th>Amount</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and equivalents</td>
<td>$3,133</td>
<td>47.08%</td>
</tr>
<tr>
<td>Less than one year</td>
<td>$3,521</td>
<td>52.92%</td>
</tr>
<tr>
<td>Total</td>
<td>$6,654</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

Presently, all of the Company’s development contract payments are denominated in U.S. dollars and, consequently, the Company believes it has no material foreign currency exchange rate risk. However, in the future Microvision may enter into development contracts or product sales in foreign currencies that may subject Microvision to foreign exchange rate risk.

ITEM 4. CONTROLS AND PROCEDURES

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report and, based on their evaluation, our principal executive officer and principal financial officer have concluded that these controls and procedures are effective. There were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, these controls. Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Securities Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

PART II
OTHER INFORMATION

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Company’s Annual Shareholder’s Meeting was held on June 9, 2004. The following proposal was introduced and voted on:

Proposal No. 1 – Election of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Votes For</th>
<th>Votes Against</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard F. Rutkowski</td>
<td>19,960,663</td>
<td>121,290</td>
</tr>
<tr>
<td>Stephen R. Willey</td>
<td>19,984,313</td>
<td>97,640</td>
</tr>
<tr>
<td>Jacqueline Brandwynne</td>
<td>18,998,786</td>
<td>1,083,167</td>
</tr>
<tr>
<td>Richard A. Cowell</td>
<td>19,767,613</td>
<td>314,340</td>
</tr>
<tr>
<td>Slade Gorton</td>
<td>19,996,613</td>
<td>85,340</td>
</tr>
<tr>
<td>Walter J. Lack</td>
<td>19,949,913</td>
<td>132,040</td>
</tr>
<tr>
<td>Robert A. Ratcliffe</td>
<td>19,974,913</td>
<td>107,040</td>
</tr>
<tr>
<td>Dennis Reimer</td>
<td>19,974,713</td>
<td>107,240</td>
</tr>
</tbody>
</table>

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits
31.1  Chief Executive Officer Certification Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2  Chief Financial Officer Certification Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 Of the Sarbanes-Oxley Act of 2002

32.1  Chief Executive Officer Certification pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2  Chief Financial Officer Certification pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(b) Reports on Form 8-K

The Company filed the following current reports on Form 8-K during the quarter ended June 30, 2004:

Current report on 8-K announcing financial results for the quarter ended March 31, 2004 as filed with the SEC on May 5, 2004.

Current report on 8-K announcing that Microvision’s majority owned subsidiary, Lumera Corporation, filed an S-1 with the SEC May 19, 2004.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MICROVISION, INC.

Date: August 9, 2004
/s/ Richard F. Rutkowski
Richard F. Rutkowski
Chief Executive Officer
(Principal Executive Officer)

Date: August 9, 2004
/s/ Jeff Wilson
Jeff Wilson
Vice President, Accounting
(Principal Accounting Officer)

EXHIBIT INDEX

The following documents are filed.

<table>
<thead>
<tr>
<th>Exhibit Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>31.1</td>
<td>Chief Executive Officer Certification Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</td>
</tr>
<tr>
<td>31.2</td>
<td>Chief Financial Officer Certification Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 Of the Sarbanes-Oxley Act of 2002</td>
</tr>
<tr>
<td>32.1</td>
<td>Chief Executive Officer Certification pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</td>
</tr>
<tr>
<td>32.2</td>
<td>Chief Financial Officer Certification pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</td>
</tr>
</tbody>
</table>
I, Richard F. Rutkowski, Chief Executive Officer and Director of the Company, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Microvision, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
   a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2004

/s/Richard F. Rutkowski
Chief Executive Officer
EXHIBIT 31.2

CERTIFICATION PURSUANT TO
RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Richard A. Raisig, Chief Financial Officer of the Company, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Microvision, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
   a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2004

/s/ Richard A. Raisig
Chief Financial Officer
CERTIFICATION PURSUANT TO
SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as chief executive officer of Microvision, Inc. (the “Company”), does hereby certify that to the undersigned’s knowledge:

1) the Company’s Form 10-Q for the quarterly period ended June 30, 2004 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) the information contained in the Company’s Form 10-Q for the quarterly period ended June 30, 2004 fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard F. Rutkowski
Richard F. Rutkowski
Chief Executive Officer

Dated: August 9, 2004
Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as chief financial officer of Microvision, Inc. (the "Company"), does hereby certify that to the undersigned's knowledge:

1) the Company’s Form 10-Q for the quarterly period ended June 30, 2004 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) the information contained in the Company’s Form 10-Q for the quarterly period ended June 30, 2004 fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard A. Raisig
Richard A. Raisig
Chief Financial Officer

Dated: August 9, 2004